Drugs / BMS-986446
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07852962 | Feb → Jul 2027 expected | — | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07780383 | Aug 2026 → Jun 2027 expected | Alzheimer disease | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT06955741 | May → Sep 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06084598 | Oct 2023 → Mar 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06268886 | Mar 2024 → Mar 2027 expected | early-onset autosomal dominant Alzheimer disease | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-01 | Bristol-Myers Squibb | Regulatory Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease bms.com ↗ |
| 2025-10-01 | Prothena Biosciences Ltd. | Regulatory Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease prothena.com ↗
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986446 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06268886 ↗ |
| Modality | Monoclonal antibody | “Anti-MTBR Tau Monoclonal Antibody” NCT06268886 ↗ |
| Route | Intravenous | “Intravenously Administered BMS-986446” NCT06084598 ↗ |